Cymwysterau
- MSc: Health Economics and Management
University of Sheffield, 2005 - BSc: Bachelor of Pharmacy
University of Wales Institute of Science and Technology, Cardiff, 1992
Rhagolwg
Mae Eifiona yn Uwch Gymrawd Ymchwil mewn Ffarmacoeconomeg yn y Ganolfan Economeg Iechyd a Gwerthuso Meddyginiaethau (CHEME) ym Mhrifysgol Bangor. Mae ganddi radd Baglor mewn Fferylliaeth o Sefydliad Gwyddoniaeth a Thechnoleg Prifysgol Cymru, Caerdydd (1992) ac yn 2005 cwblhaodd radd Meistr mewn Economeg a Rheolaeth Iechyd ym Mhrifysgol Sheffield.
Ar ôl graddio o Gaerdydd, treuliodd Eifiona 8 mlynedd fel fferyllydd ysbyty yn arbenigo mewn oncoleg, darparu gwasanaethau clinigol, cyllid a chymorth busnes yn y DU ac yn Awstralia. Yn dilyn ymlaen o hyn, dilynodd Eifiona yrfa mewn economeg iechyd yn y diwydiant fferyllol ac yn yr amgylchedd ymgynghori, gan weithio ar ystod eang o brosiectau gan gynnwys datblygu ac addasu modelau economaidd iechyd, modelau effaith cyllideb, astudiaethau cost salwch, cyflwyniadau HTA, cyffuriau amddifad (orphan drugs) a dadansoddiadau amgylcheddol.
Mae hi'n brofiadol mewn amrywiaeth o feysydd therapi gan gynnwys oncoleg, niwroleg, anadlu, ffrwythlondeb ac iechyd meddwl. Mae gan Eifiona brofiad eang hefyd o ddatblygu gwerth cyfathrebu, llawysgrifau a phosteri, ac mae wedi cyd-awduro papurau a adolygwyd gan gymheiriaid mewn economeg iechyd.
Ymunodd Eifiona â CHEME yn 2015, ac ar hyn o bryd mae'n gweithio ar ystod o brosiectau ffarmaco-economaidd, gan gynnwys treial NERVES (sciatica), astudiaeth CF Start (ffibrosis systig) a'r astudiaeth CASTLE (plant gyda epilepsi) . Mae hi hefyd yn cynnal adolygiad cymheiriaid o gyflwyniadau Grŵp Strategaeth Meddyginiaethau Cymru Gyfan ac yn darparu cefnogaeth economaidd iechyd i Ganolfan Therapiwteg a Thocsicoleg Cymru Gyfan.
Cyhoeddiadau
2021
- Wedi ei Dderbyn / Yn y wasgA Randomised Controlled Trial of Surgical Microdiscectomy versus Trans-foraminal Epidural Steroid Injection for sciatica of up to 1 year; the NERVES trial
Wilby, M. J., Best, A., Wood, E., Burnside, G., Bedson, E., Short, H., Wheatley, D., Hill-McManus, D., Sharma, M., Clark, S., Baranidharan, G., Price, C., Mannion, R., Hutchinson, P. J., Hughes, D., Marson, A. G. & Williamson, P., 26 Ion 2021, (Wedi ei Dderbyn / Yn y wasg) Yn : The Lancet Rheumatology.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2020
- CyhoeddwydThe new and non-transparent Cancer Drugs Fund
Wood, E. & Hughes, D., Ion 2020, Yn : PharmacoEconomics. 38, 1, t. 1-4
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2019
- CyhoeddwydAdalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
Ramanan, A. V., Dick, A. D., Jones, A. P., Hughes, D., McKay, A., Rosala_Hanna, A., Williamson, P. R., Hardwick, B., Hickey, H., Rainford, N., Kolamunnage-Dona, R., Culeddu, G., Plumpton, C., Wood, E., Compeyrot-Lacassagne, S., Woo, P., Eldesten, C. & Beresford, M. W., 10 Ebr 2019, Yn : Health Technology Assessment. 23, 15, t. 1-174 174 t.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl - CyhoeddwydCost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis
Hughes, D. A., Culeddu, G., Plumpton, C. O., Wood, E., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot Lacassagne, S., Hardwick, B., Hickey, H., Woo, P., Beresford, M. W. & Ramanan, A. V., Maw 2019, Yn : Ophthalmology. 126, 3, t. 415-424
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl - CyhoeddwydCost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis: Authors’ reply.
Hughes, D., Culeddu, G., Plumpton, C., Wood, E., Dick, A. D., Beresford, M. W. & Ramanan, A. V., Maw 2019, Yn : Ophthalmology. 126, 3, t. e24-e25
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Llythyr
2018
- CyhoeddwydLessons learnt from a discontinued randomised controlled trial: Adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)
Williams, N., Jenkins, A., Goulden, N., Hoare, Z., Hughes, D., Wood, E., Foster, N. E., Walsh, D. A., Carnes, D., Sparkes, V., Hay, E. M., Isaacs, J., Konstantinou, K., Morrissey, D., Karppinen, J., Genevay, S. & Wilkinson, C., 31 Gorff 2018, Yn : Trials. 19, 408.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2017
- CyhoeddwydSubcutaneous Injection of Adalimumab Trial compared with Control (SCIATiC): a randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica
Williams, N. H., Jenkins, A., Goulden, N., Hoare, Z., Hughes, D. A., Wood, E., Foster, N. E., Walsh, D. A., Carnes, D., Sparkes, V., Hay, E. M., Isaacs, J., Konstantinou, K., Morrissey, D., Karppinen, J., Genevay, S. & Wilkinson, C., 31 Hyd 2017, Yn : Health Technology Assessment. 21, 60, t. 1-180 180 t.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2016
- CyhoeddwydConducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
Hughes, D., Charles, J. M., Dawoud, D. M., Edwards, R. T., Holmes, E. A., Jones, C. L., Parham, P., Plumpton, C., Ridyard, C. O., Lloyd-Williams, H., Wood, E. M. & Yeo, S., Mai 2016, Yn : Pharmacoeconomics. 34, 5, t. 447-461
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2015
- CyhoeddwydNICE recommendations: why no disinvestment recommendations to offset investment decisions?
Hughes, D., Tuersley, L. V., Hughes, D. A., Wood, E. M. & Tuersley, L., 19 Mai 2015, Yn : BMJ. 350
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2011
- CyhoeddwydA cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK
Lowin, J., Bergman, A., Chaudhuri, K. R., Findley, L. J., Roeder, C., Schifflers, M., Wood, E. & Morris, S., 6 Gorff 2011, Yn : Journal of Medical Economics. 14, 5, t. 584-93 10 t.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl - CyhoeddwydThe economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset
Findley, L. J., Wood, E., Lowin, J., Roeder, C., Bergman, A. & Schifflers, M., 17 Ion 2011, Yn : Journal of Medical Economics. 14, 1, t. 130-9 10 t.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2010
- CyhoeddwydCost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
Asukai, Y., Valladares, A., Camps, C., Wood, E., Taipale, K., Arellano, J., Cassinello, A., Sacristán, J. A. & Dilla, T., 29 Ion 2010, Yn : BMC Cancer. 10, t. 26
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
2004
- CyhoeddwydAxillary staging for operable primary breast cancer
Hind, D., Wyld, L., Wood, E., Beverley, C. & Reed, M. W., 19 Gorff 2004, Yn : Cochrane Database of Systematic Reviews. 2004, 3, CD004561.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl
Gweithgareddau
2020
- CASTLE (Changing agendas on sleep, treatment & learning in epilepsy)
The CASTLE study is focused on rolandic epilepsy, which is the most common type of childhood epilepsy and affects about one-sixth of all children with epilepsy in the UK.
Throughout the CASTLE study, we’ll be working with children, parents, doctors and nurses to choose the best ways to measure health and quality of life for children with epilepsy. The research will also include talking to parents and children about their experiences in relation to sleep, taking medication, learning and how taking part in the study has impacted on them.
9 Maw 2020 – 5 Rhag 2023
Cysylltau:
Gweithgaredd: Arall (Cyfrannwr)
2019
- Pharmaceoeconomics Short Course, Bangor University
13 Medi 2019
Gweithgaredd: Cymryd rhan mewn gweithdy, seminar, cwrs (Siaradwr) - Health Services Research Summer School
11 Gorff 2019
Gweithgaredd: Cymryd rhan mewn gweithdy, seminar, cwrs (Siaradwr) - AWTTC 2019-20 health economics support in relation to the assessment of new medicines
2019 – 2020
Gweithgaredd: Arall (Cyfrannwr)
2018
- CF-START (Cystic Fibrosis [CF] anti-staphylococcal antibiotic prophylaxis trial)
The aim of the CF START trial is determine the safest and most effective way to treat infants diagnosed with Cystic Fibrosis (CF) with antibiotics. At the moment infants in the UK are prescribed an antibiotic, usually flucloxacillin, every day to prevent infection with a bacteria (bug) called Staphylococcus aureus (SA).
Although this approach appears to help prevent SA infection, there is a worry that it may make earlier infection with other bugs, such as Pseudomonas aeruginosa (PsA) more likely.
This trial is designed to test if infants with CF are more likely to get an earlier infection from PsA if they are taking flucloxacillin on a daily basis (“Prevent and Treat”) or Antibiotics in a more targeted manner (“Detect and Treat”).
1 Medi 2018
Cysylltau:
Gweithgaredd: Arall (Cyfrannwr) - Developing a repurposed medicine for Duchenne muscular dystrophy
1 Awst 2018
Gweithgaredd: Arall (Cyfrannwr) - Health Services Research Summer School, Bangor University
6 Gorff 2018
Gweithgaredd: Cymryd rhan mewn gweithdy, seminar, cwrs (Siaradwr) - Pharmaceoeconomics Short Course, Bangor University
13 Ebr 2018
Gweithgaredd: Cymryd rhan mewn gweithdy, seminar, cwrs (Siaradwr) - AWTTC 2018-19 health economics support in relation to the assessment of new medicines
2018 – 2019
Gweithgaredd: Arall (Cyfrannwr)
2017
- AWTTC 2017-18 health economics support in relation to the assessment of new medicines
2017 – 2018
Gweithgaredd: Arall (Cyfrannwr)
2016
- SYCAMORE (effectiveness of adalumimab in the treatment of juvenile paediatric uveitis)
1 Medi 2016 – 1 Medi 2018
Gweithgaredd: Arall (Cyfrannwr) - AWTTC 2016-17 health economics support in relation to the assessment of new medicines
2016 – 2107
Gweithgaredd: Arall (Cyfrannwr)
2015
- NERVES (effectiveness of trans-foraminal epidural steroid injections)
1 Maw 2015 – 30 Medi 2019
Cysylltau:
Gweithgaredd: Arall (Cyfrannwr)
2013
- New Medicines Group (Sefydliad allanol)
Deputy Health Economist, New Medicines Group
2013 – 2016
Gweithgaredd: Aelodaeth o bwyllgor (Aelod)